Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations
暂无分享,去创建一个
P. Chanson | L. Cohen | F. Casanueva | P. Cohen | S. Melmed | M. Bidlingmaier | P. Backeljauw | J. Frystyk | A. Juul | D. Clemmons | J. Kopchick | M. Haymond | M. Thorner | C. Strasburger | J. Christiansen | J. Holly | G. Johannsson | R. Ross | C. S. Choong | B. Biller | M. Misra | P. Saenger | C. Höybye | A. Hoffman | Y. Hasegawa | R. Rosenfeld | B. Miller | R. Horikawa | V. Popović | L. Katznelson | K. Ho | J. Holly | Kuk-Wha Lee | M. Boguszewski | K. Yuen | Judith L. Ross | A. Grimberg | Haim Werner | Xiaoping Luo | K-O Lee | J. Jørgensen | Pierre Chatelain | K. O. Lee | Catherine S. Choong
[1] Dong Liu,et al. Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children , 2015, Drug design, development and therapy.
[2] D. Dunger,et al. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults , 2015, European journal of endocrinology.
[3] A. Hoffman,et al. Status of long-acting-growth hormone preparations--2015. , 2015, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.
[4] T. Reinehr,et al. Low Treatment Adherence in Pubertal Children Treated with Thyroxin or Growth Hormone , 2015, Hormone Research in Paediatrics.
[5] G. Gamble,et al. Three‐year experience with access to nationally funded growth hormone (GH) replacement for GH‐deficient adults , 2015, Clinical endocrinology.
[6] C. Sklar,et al. Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy--A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee. , 2015, The Journal of clinical endocrinology and metabolism.
[7] A. Hoffman,et al. Growth Hormone Safety Workshop Position Paper: a , 2015 .
[8] G. Armstrong,et al. Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the childhood cancer survivor study. , 2014, The Journal of clinical endocrinology and metabolism.
[9] U. Meinhardt,et al. Parent preference in Switzerland for easy-to-use attributes of growth hormone injection devices quantified by willingness to pay , 2014, Expert review of medical devices.
[10] P. Lopez,et al. 24-month use of once-weekly GH, LB03002, in prepubertal children with GH deficiency. , 2014, The Journal of clinical endocrinology and metabolism.
[11] J. Argente,et al. Identification and management of poor response to growth‐promoting therapy in children with short stature , 2012, Clinical endocrinology.
[12] N. Møller,et al. Growth hormone (GH)-induced insulin resistance is rapidly reversible: an experimental study in GH-deficient adults. , 2011, The Journal of clinical endocrinology and metabolism.
[13] J. Roemmler,et al. Effects of once-weekly sustained-release growth hormone: a double-blind, placebo-controlled study in adult growth hormone deficiency. , 2011, The Journal of clinical endocrinology and metabolism.
[14] A. Gunn,et al. Non-Compliance with Growth Hormone Treatment in Children Is Common and Impairs Linear Growth , 2011, PloS one.
[15] L. Dunkel,et al. A Comparison of Different Definitions of Growth Response in Short Prepubertal Children Treated with Growth Hormone , 2011, Hormone Research in Paediatrics.
[16] Gitte Schøning Fuchs,et al. Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test. , 2009, Clinical therapeutics.
[17] P. Touraine,et al. Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH. , 2009, European journal of endocrinology.
[18] M. Ranke,et al. Predicting growth in response to growth hormone treatment. , 2009, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.
[19] P. Cohen,et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. , 2008, The Journal of clinical endocrinology and metabolism.
[20] R. Rosenfeld,et al. Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. , 2008, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[21] M. Tauber,et al. Observations of nonadherence to recombinant human growth hormone therapy in clinical practice. , 2008, Clinical therapeutics.
[22] D. Dunger,et al. Monitoring of concordance in growth hormone therapy , 2007, Archives of Disease in Childhood.
[23] A. Hoffman,et al. Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency. , 2005, The Journal of clinical endocrinology and metabolism.
[24] Gerard Conway,et al. Regarding the consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. , 2003, The Journal of clinical endocrinology and metabolism.
[25] C. Gravholt,et al. Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults. , 2001, The Journal of clinical endocrinology and metabolism.
[26] C. Cowell,et al. Safety issues in children and adolescents during growth hormone therapy--a review. , 2000, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.
[27] M. Thorén,et al. The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender. , 1996, The Journal of clinical endocrinology and metabolism.
[28] P. Björntorp,et al. Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults. II. Effects on serum lipoproteins and lipoprotein and hepatic lipase activity. , 1996, Metabolism: clinical and experimental.
[29] J. Jørgensen,et al. Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients. , 1995, The Journal of clinical endocrinology and metabolism.
[30] K. Alberti,et al. Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites. , 1990, The Journal of clinical endocrinology and metabolism.
[31] Z. Laron,et al. THE EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY , 1968 .